Terapevticheskii arkhivTerapevticheskii arkhivТерапевтический архив0040-36602309-5342LLC Obyedinennaya Redaktsiya30982Editorial articleПередовая статьяResearch ArticleBronchial asthma: new prospects in therapyБронхиальная астма: новые перспективы в терапииChuchalinA GЧучалинАлександр Григорьевич

д-р мед. наук, проф., акад РАМН, дир. НИИ пульмонологии

chuchalin@inbox.ruResearch Institute of PulmonologyФГУ НИИ пульмонологии ФМБА России15032012843NO3 (2012)ТОМ 84, №3 (2012)51110042020Copyright ©; 2012, Consilium MedicumCopyright ©; 2012, ООО "Консилиум Медикум"2012Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://ter-arkhiv.ru/0040-3660/article/view/30982

The article reviews original and literature data on the use of monoclonal antibodies (MAB) for treatment of patients with severe bronchial asthma (BA), methods of MAB obtaining. Biomolecule targets in BA are some immunoglobulins, CD4 lymphosytes and TNFalpha. Successful use of monoclonal anti-IgE antibodies in BA by Russian clinicians in 1980s and current experience with administration of foreign MAB drugs (omalizumab, mepolizumab, infliximab, etc.) are considered.

В статье приводятся собственные данные и обзор результатов исследований других авторов о применении моноклональных антител (МАТ) для лечения больных с тяжелой формой бронхиальной астмы (БА). Представлены сведения о методах получения МАТ. Мишенями биомолекул при БА являются ряд иммуноглобулинов, CD4 лимфоциты и α-фактор некроза опухоли. Отмечено успешное применение моноклональных анти-1gЕ-антител в 80-х годах прошлого столетия в отечественной клинике. Освещены сведения о применении при БА созданных в зарубежных клиниках препаратов — МАТ (омализумаб, меполизумаб, инфликсимаб и др.).

bronchial asthmatreatmentmonoclonal antibodiesrecombinant bioengineeringomalizumabбронхиальная астмалечениемоноклональные антителарекомбинантная биоинженерияомализумабAbbas A. Cellular and Molecular immunology. 6th ed. Amsterdam: Elsevier, 2010.Lee S. J., Chinen J., Kavanaugh A. Immunomodulator therapy: monoclonal antibodies, fusion proteins, cytokines and immunoglobulin’s. J. Allergy Clin. Immunol. 2010; 125 (Suppl. 2): S314—S323.Чучалин А. Г., Раудла Л. А., Татарский А. Р. и др. Экстракорпоральная специфическая иммуносорбция в комплексной терапии у больных бронхиальной астмой с гиперчувствительностью к аллергену домашней пыли. Тер. арх. 1984; 6: 24-28Чучалин А. Г., Шуркалин Б. К., Евсеев Н. Г. и др. Иммуносорбция в терапии атопической бронхиальной астмы. В кн.: Новые средства и сферы клинического применения сорбиционной детоксикации организма. Днепропетровск, 1985; 141—143.Устинов А. Г., Давидов Д. Я., Зарубина Т. В. и др. Состояние сердечно-сосудистой и респираторной систем при проведении иммуносорбции. Тер. арх. 1986; 4; 38—40.Chuchalin A. G., Kazanbiyev D. N., Mavrayev D. E. et al. Extracorporeal immunoadsorption in treatment of bronchial asthma. In: Proceeding of XIII Congress of European academy of allergology and clinical immunology. Budapest; 1986: 491—502.Lebedin Y. S., Gorchakov V. D., Petrova E. N. et al. Ex vivo removal of IgE in atopic asthma by extracorporeal plasmoimmunoadsorption (EPIA): development of a clinical adsorbent. Int. J. Artif. Organs 1991; 14 (8): 508—515.Shields R. L., Werther W. R., Zioncheck K. et al. Anti-IgE monoclonal antibodies that inhibit allergen-specific histamine release // Int. Arch. Allergy Immunol. 1995; 107: 412—13.Noga O., Hanf G., Kunkel G., Kleine-Tebbe J. Basophil histamine release decreases during omalizumab therapy in allergic asthmatics. Int. Arch. Immunol. 2008; 146 (1): 66—70.Rudolf M. P., Zuercher A. W., Nechansky A. et al. Molecular basis for nonanaphylactogenicity of a monoclonal anti-IgE antibody. J. Immunol. 2000; 165 (2): 813—819.Hayashi N., Tsucamoto Y., Sallas W., Lowe P. A. mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab. Br. J. Clin. Pharmacol. 2006; 63 (5): 548—561.Holgate S. T., Chuchalin A. G. Efficacy and safety of recombinant anti-immunoglobulin E antibody in severe allergic asthma. Clin. exp. allergy 2004; 34: 632—638.Bousquet J., Cabrera P., Berkman N. et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbation and emergency medical visits in patients with severe persistent asthma. Allergy 2005; 60: 303—308.Limb S. L., Starke P. R., Lee C. E., Chowdhury B. A. Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma. J. Allergy Clin. Immunol. 2007; 120: 1378—1381.Сох L. S. How safe are the biologicals in treating asthma and rhinitis? Allergy Asthma Clin. Immunol. 2009; 5 (1): 4.Singh J., Kraft M. Anti-IgE and other antibody targets in asthma. Handb. Exp. Pharmacol. 2008; 181: 257—288.Leckie M. J., Brinke A., Diamant Z. et al. Effects of interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper responsiveness and the late asthmatic response. Lancet 2000; 356: 2144—2148.Flood-Page P., Swenson C., Faiferman I. et al. A study of evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am. J. Respir. Crit. Care Med. 2007; 176: 1062—1071.Kips J. C., O’Conner B. J., Langley S. J. et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am. J. Respir. Crit. Care Med. 2003; 167: 1655—1659.Haldar P., Brightling C. E., Hargadon B. et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N. Engl. J. Med. 2009; 360: 973—984.Koike M., Nakamura K., Furuya A. et al. Establishment of humanized anti-interleukin-5 receptor alpha chain monoclonal antibodies having a potent neutralizing activity. Hum. Antibod. 2009; 18: 17—27.Busse W. W., Katial R., Gossage D. et al. Safety profile, pharmacokinetics and biological activity MEDI-563, anti-IL-5 receptor alpha antibody, in phase 1 study of subjects with mild asthma. J. Allergy Clin. Immunol. 2009; 125: 1237—1244.Gruenberg D., Busse W. W. Biological therapies for asthma. Curr. Opin. Pulm. Med. 2010; 16: 19—24.Erin E. M., Leaker B. R., Nicholson G. C. et al. The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma. Am. J. Respir. Crit. Care Med. 2006; 174: 753—762.Wenzel S. E., Barnes P. J., Bleecker E. R. et al. A randomized, doubleblind, placebo-controlled study of tumor necrosis factor-alpha blocked in severe persistent asthma. Am. J. Respir. Crit. Care Med. 2009; 179: 549—558.Howarth P. H., Babu K. S., Arshad H. S. et al. Tumor necrosis factor (TNF-alpha) as a novel therapeutic target in symptomatic corticosteroid dependet asthma. Thorax 2005; 60: 1012—1018.Doherty T., Broide D. Cytokines and growth factors in airway remodeling in asthma. Curr. Opin. Immunol. 2007; 19: 676-680.Busse W. W., Israel E., Nelson H. S. et al. Daclizumab improves asthma control in patients with moderate to severe persistent asthma: a randomized controlled trial. Am. J. Respir. Crit. Care Med. 2008; 178: 1002—1008.Hart T. K., Blackburn M. N., Brigham-Burke M. et al. Preclinical efficacy and safty of pascolizumab: a humanized anti-interleukin-4 antibody with therapeutic potential in asthma. Clin. Exp. Immunol. 2002; 130: 93—100.Long A. A. Monoclonal antibodies and other biological agents in treatment of asthma. MAbs 2009; 1: 237—246.Poole J. A., Meng J., Reff M. et al. Anti-CD23 monoclonal antibody, lumiliximab, inhibited allergen-induced responses in antigen-presenting cells and T cells from atopic subjects. J. Allergy Clin. Immunol. 2005; 116: 780—788.Kon O. M., Sihra B. S., Compton C. H. et al. (1998) Randomized dose-ranging placebo-controlled study of chemeric antibody to CD4 (keliximab) in chronic severe asthma. Lancet 1998; 352: 1109—1113.Corren J., Busse W., Meltzer E. O. et al. A randomized controlled phase 11 study of AMG317, an IL4Ralpha antagonist in patients with asthma. Am. J. Respir. Crit. Care Med. 2010; 181: 788—796.